Targeting the RXR pathway for the prevention of triple-negative breast cancer.

被引：1
|
作者：
Moyer, Cassandra [1 ]
Hill, Jamal [1 ]
Coleman, Darian [1 ]
Sei, Shizuko [2 ]
Mohammed, Altaf [2 ]
Sanders, Martin [3 ]
Brown, Powel [1 ]
Mazumdar, Abhijit [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] NCI, Rockville, MD USA
[3] Io Therapeut Inc, Santa Ana, CA USA
来源：
CANCER PREVENTION RESEARCH | 2023年 / 16卷 / 01期
关键词：
D O I：
10.1158/1940-6215.PrecPrev22-P004
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P004
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer.
    O'Shaughnessy, Joyce
    Osborne, Cynthia
    Pippen, John E.
    Yoffe, Mark
    Patt, Debra
    Rocha, Christine
    Koo, Ingrid Chou
    Sherman, Barry M.
    Bradley, Charles
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (03): : 205 - 214
  • [32] MYC as a therapeutic target for the treatment of triple-negative breast cancer.
    Foley, Sarah A.
    Casten, Alina
    Kavanagh, Emma
    Synnott, Naoise C.
    Crown, John
    Larsson, Lars-Gunnar
    Duffy, Michael J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [33] Distinct immune microenvironments stratify triple-negative breast cancer.
    Gruosso, Tina
    Kumar, Venkata Satya
    Gigoux, Mathieu
    Saleh, Sadiq
    Bertos, Nicholas
    Omeroglu, Atilla
    Zuo, Dongmei
    Meterissian, Sarkis
    Haibe-Kains, Benjamin
    Park, Morag
    [J]. MOLECULAR CANCER RESEARCH, 2018, 16 (08) : 17 - 17
  • [34] Patterns of mutation enrichment in metastatic triple-negative breast cancer.
    Saravia, Cesar H.
    Flores, Claudio J.
    Schwarz, Luis Jesus
    Bravo, Leny
    Zavaleta, Jenny
    Araujo, Jhajaira M.
    Neciosup, Silvia P.
    Pinto, Joseph A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [35] Characterizing the gut microbiome of patients with triple-negative breast cancer.
    Swoboda, April T.
    Sharma, Anukriti
    Olopade, Olufunmilayo I.
    Nanda, Rita
    Gilbert, Jack
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [36] The prognostic impact of age in patients with triple-negative breast cancer.
    Liedtke, C.
    Gluz, D.
    Kiesel, L.
    Hortobagyi, G. N.
    Pusztai, L.
    Gonzalez-Angulo, A. M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [37] Expression of novel immunotherapeutic targets in triple-negative breast cancer.
    Basu, Gargi Dan
    Ghazalpour, Anatole
    Gatalica, Zoran
    Anderson, Karen S.
    McCullough, Ann E.
    Spetzer, David B.
    Pockaj, Barbara A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [38] ADAMs as new therapeutic targets for triple-negative breast cancer.
    Mullooly, M.
    McGowan, P. M.
    Sukor, S. U.
    Madden, S. F.
    McDermott, E.
    Crown, J.
    O'Donovan, N.
    Duffy, M. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [39] A gene expression signature of MEK pathway activation to predict survival in triple-negative breast cancer.
    Balko, Justin M.
    Sanders, Melinda
    Gabriela Kuba, Maria
    Pinto, Joseph A.
    Doimi, Franco F.
    Leonidas Gomez, Henry
    Arteaga, Carlos L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [40] BCL11A—targeting triple-negative breast cancer?
    Alessia Errico
    [J]. Nature Reviews Clinical Oncology, 2015, 12 (3) : 127 - 127
12345